| Min | Max | |
|---|---|---|
| Investment Target | £400,000 | £2,000,000 |
| Share Price | £0.50 | £0.50 |
Shares Offered
|
800,000 | 4,000,000 |
|
Percentage Offered
|
3.85% | 16.67% |
|
Shares Issued
|
20,000,000 | |
| Pre-money Valuation | £10,000,000 | |
| Share Type | Ordinary | |
| Minimum Investment | £100.00 | |
| Tax Relief Available | EIS | |
| Sector | Healthcare & Pharmaceuticals | |
| Location | London, United Kingdom | |
| Company Number | 11845112  |
|
CBD Science Group seeks to help cancer patients with chronic pain. At present, there are an estimated 3 million people suffering from cancer in the UK, with 1,000 new patients diagnosed daily. 33% of those who suffer from cancer pain are currently undertreated. For patients that do not have medical contraindications, current treatments are ineffective and inflict severe side effects. These are patients already in a vulnerable condition suffering greatly. The opioid epidemic is fast becoming a serious cause for concern in the UK. Opioid painkillers are seen to induce side effects such as nausea, drowsiness, muscular pain and anxiety. Their addictive nature is causing repeated misuse and ultimately have been shown to trigger substance use disorders (SUD). Plant-based cannabinoid medicines present a real solution to this real issue and provide a great opportunity to deliver a safe and effective pain treatment for those with urgent and unmet needs.
CBD Science Group has identified this unmet medical need and has initiated Real-World Evidence (RWE) clinical trials.
Under the guidance of a leading Clinical Advisory Board, overseen by former NHS Deputy Medical Director, Professor Mike Bewick, the company will launch its Real World Evidence (RWE) trial. Under the trial, evidence will be gathered on cancer patients suffering from chronic pain where current treatments are ineffective. Patient-level clinical evidence will be used to assess the value of treatments based on real health outcomes in the Real World setting.
The clinical trial will take place over 3-4 months, after which NHS Hospital Trusts are obligated to pay for ongoing treatments, with anticipated annual revenues of £3.6 million for every 1,000 patients. The estimated patient pool is greater than 650,000 patients in the UK, with patient recruitment for the trial commencing in Q4 2021. Confirmed hospital research centres include Royal Marsden Trust (Europe’s Leading Cancer Centre), Birmingham, Manchester, Belfast and Leeds. Promising discussions with Glasgow, Cardiff, St Thomas & Guys and Nottingham are ongoing as CBD Science seeks to further expand operations across the UK.
Furthermore, highly sought-after endorsements have been received from a number of key industry bodies, including, the National Cancer Research Institute (NCRI), the Medicines and Healthcare product Regulatory Agency (MHRA), Northwest EHealth (NWEH), and the Royal Marsden Trust.
A suite of modern technologies, including smartwatches, will support CBD Science with capturing data in clinical settings and beyond. This will include an implementation of immediate diagnostic algorithms that will help to alleviate suffering, while also monitoring positive and adverse effects on a patient by patient basis.
Medicinal cannabis has been legal in the UK since November 2018. The market is large and growing, with Prohibition Partners estimating a total medicinal cannabis market value of £7.7 billion by 2028. A number of companies are already seeing success in this new market, including the largest UK based cannabinoid company, GW Pharma, which was recently acquired by Jazz Pharmaceuticals for £5.3 billion.
The company has received support from a number of Key Stakeholders including:
| • MHRA – Medicines Healthcare Regulatory Agency • CPRD – Clinical Practice Research Database • NWEH – North-West EHealth • NIHR – National Institute for Health Research • NCRI – National Cancer Research Institute • Royal Marsden Hospital Trust Committed |
 |
Expected Annual Revenue per Patient: £3,650
To find out more about this pitch or to ask the Director(s) a question please Join Now or Log in below
|
|
|
|
Discover investment opportunities, support companies you believe in and share their success Take advantage of SEIS/EIS tax relief to minimize your tax and the opportunity to obtain high-interest rates.
With us, you can gain access to great UK companies offering Shares, Crowd Bonds or Digitalised Assets through our easy to use online platform.
To find out more about this pitch or to ask the Director(s) a question please Join Now or Log in below
|
|
|
|
Discover investment opportunities, support companies you believe in and share their success Take advantage of SEIS/EIS tax relief to minimize your tax and the opportunity to obtain high-interest rates.
With us, you can gain access to great UK companies offering Shares, Crowd Bonds or Digitalised Assets through our easy to use online platform.
To find out more about this pitch or to ask the Director(s) a question please Join Now or Log in below
|
|
|
|
Discover investment opportunities, support companies you believe in and share their success Take advantage of SEIS/EIS tax relief to minimize your tax and the opportunity to obtain high-interest rates.
With us, you can gain access to great UK companies offering Shares, Crowd Bonds or Digitalised Assets through our easy to use online platform.
To find out more about this pitch or to ask the Director(s) a question please Join Now or Log in below
|
|
|
|
Discover investment opportunities, support companies you believe in and share their success Take advantage of SEIS/EIS tax relief to minimize your tax and the opportunity to obtain high-interest rates.
With us, you can gain access to great UK companies offering Shares, Crowd Bonds or Digitalised Assets through our easy to use online platform.
To find out more about this pitch or to ask the Director(s) a question please Join Now or Log in below
|
|
|
|
Discover investment opportunities, support companies you believe in and share their success Take advantage of SEIS/EIS tax relief to minimize your tax and the opportunity to obtain high-interest rates.
With us, you can gain access to great UK companies offering Shares, Crowd Bonds or Digitalised Assets through our easy to use online platform.
| Min | Max | |
|---|---|---|
| Investment Target | £400,000 | £2,000,000 |
| Share Price | £0.50 | £0.50 |
|
Shares Offered
|
800,000 | 4,000,000 |
|
Percentage Offered
|
3.85% | 16.67% |
|
Shares Issued
|
20,000,000 | |
| Pre-money Valuation | £10,000,000 | |
| Share Type | Ordinary | |
| Minimum Investment | £100.00 | |
| Tax Relief Available | EIS | |
| Sector | Healthcare & Pharmaceuticals | |
| Location | London, United Kingdom | |
| Company Number | 11845112 |
|
Register in minutes